Investment Analysts’ Price Target Changes for November 5th (ARCB, ARM, BALL, BLLN, BRKR, CPAY, CRCL, CRTO, CYTK, EMR)

Investment Analysts’ price target changes for Thursday, November 5th:

ArcBest (NASDAQ:ARCB) had its price target raised by Citigroup from $170.00 to $175.00. They currently have a buy rating on the stock.

ARM (NASDAQ:ARM) had its price target reduced by JPMorgan Chase & Co. from $255.00 to $245.00. The firm currently has an overweight rating on the stock.

Ball (NYSE:BALL) had its price target increased by Citigroup from $75.00 to $77.00. Citigroup currently has a buy rating on the stock.

Billiontoone (NASDAQ:BLLN) had its target price increased by JPMorgan Chase & Co. from $130.00 to $135.00. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Bruker (NASDAQ:BRKR) had its price target boosted by Citigroup from $53.00 to $64.00. The firm currently has a neutral rating on the stock.

Corpay (NYSE:CPAY) had its target price increased by JPMorgan Chase & Co. from $470.00 to $500.00. The firm currently has an overweight rating on the stock.

Circle Internet Group (NYSE:CRCL) had its price target trimmed by JPMorgan Chase & Co. from $110.00 to $100.00. The firm currently has an overweight rating on the stock.

Criteo (NASDAQ:CRTO) had its target price reduced by Citigroup from $23.00 to $21.00. The firm currently has a buy rating on the stock.

Cytokinetics (NASDAQ:CYTK) had its price target boosted by Citigroup from $99.00 to $105.00. Citigroup currently has a buy rating on the stock.

Emerson Electric (NYSE:EMR) had its target price increased by Citigroup from $182.00 to $198.00. The firm currently has a buy rating on the stock.

Enovis (NYSE:ENOV) had its price target raised by Needham & Company LLC from $34.00 to $38.00. They currently have a buy rating on the stock.

EPAM Systems (NYSE:EPAM) had its target price increased by Needham & Company LLC from $120.00 to $200.00. The firm currently has a buy rating on the stock.

Edwards Lifesciences (NYSE:EW) had its target price boosted by JPMorgan Chase & Co. from $105.00 to $120.00. They currently have an overweight rating on the stock.

Expedia Group (NASDAQ:EXPE) had its target price cut by JPMorgan Chase & Co. from $330.00 to $315.00. They currently have a neutral rating on the stock.

Fair Isaac (NYSE:FICO) had its target price trimmed by JPMorgan Chase & Co. from $900.00 to $800.00. JPMorgan Chase & Co. currently has a neutral rating on the stock.

Figma (NYSE:FIG) had its price target trimmed by JPMorgan Chase & Co. from $28.00 to $24.00. JPMorgan Chase & Co. currently has a neutral rating on the stock.

Flywire (NASDAQ:FLYW) had its price target boosted by Citigroup from $19.00 to $23.00. They currently have a neutral rating on the stock.

GlobalFoundries (NASDAQ:GFS) had its target price trimmed by Citigroup from $58.00 to $46.00. The firm currently has a neutral rating on the stock.

GXO Logistics (NYSE:GXO) had its price target raised by Citigroup from $65.00 to $66.00. Citigroup currently has a buy rating on the stock.

GXO Logistics (NYSE:GXO) had its price target boosted by JPMorgan Chase & Co. from $68.00 to $73.00. JPMorgan Chase & Co. currently has an overweight rating on the stock.

HubSpot (NYSE:HUBS) had its target price lowered by JPMorgan Chase & Co. from $240.00 to $224.00. They currently have a neutral rating on the stock.

IDEAYA Biosciences (NASDAQ:IDYA) had its price target raised by Citigroup from $65.00 to $66.00. The firm currently has a buy rating on the stock.

International Flavors & Fragrances (NYSE:IFF) had its target price increased by Citigroup from $100.00 to $105.00. Citigroup currently has a buy rating on the stock.

Ligand Pharmaceuticals (NASDAQ:LGND) had its target price increased by Citigroup from $397.00 to $402.00. They currently have a buy rating on the stock.

Lumen Technologies (NYSE:LUMN) had its price target lowered by JPMorgan Chase & Co. from $7.00 to $6.00. They currently have a neutral rating on the stock.

McDonald’s (NYSE:MCD) had its price target increased by JPMorgan Chase & Co. from $250.00 to $270.00. They currently have an overweight rating on the stock.

Medline (NASDAQ:MDLN) had its price target boosted by Citigroup from $45.00 to $47.00. Citigroup currently has a buy rating on the stock.

Mayville Engineering (NYSE:MEC) had its target price reduced by Citigroup from $38.00 to $27.00. The firm currently has a buy rating on the stock.

Mplx (NYSE:MPLX) had its target price raised by Citigroup from $55.00 to $56.00. They currently have a neutral rating on the stock.

Motorola Solutions (NYSE:MSI) had its price target boosted by JPMorgan Chase & Co. from $545.00 to $570.00. JPMorgan Chase & Co. currently has an overweight rating on the stock.

NOV (NYSE:NOV) had its target price lowered by Citigroup from $21.00 to $20.00. Citigroup currently has a neutral rating on the stock.

PayPay (NASDAQ:PAYP) had its price target cut by Citigroup from $18.00 to $17.00. The firm currently has a neutral rating on the stock.

Insulet (NASDAQ:PODD) had its price target increased by Citigroup from $150.00 to $170.00. They currently have a neutral rating on the stock.

Pattern Group (NASDAQ:PTRN) had its target price raised by JPMorgan Chase & Co. from $27.00 to $29.00. They currently have an overweight rating on the stock.

Qualcomm (NASDAQ:QCOM) had its target price reduced by JPMorgan Chase & Co. from $215.00 to $200.00. The firm currently has a neutral rating on the stock.

Ralliant (NYSE:RAL) had its target price raised by Citigroup from $85.00 to $88.00. They currently have a buy rating on the stock.

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price cut by Citigroup from $32.00 to $22.00. Citigroup currently has a buy rating on the stock.

Rapid7 (NASDAQ:RPD) had its price target increased by Citigroup from $13.00 to $16.00. They currently have a neutral rating on the stock.

Royalty Pharma (NASDAQ:RPRX) had its price target raised by Citigroup from $70.00 to $78.00. The firm currently has a buy rating on the stock.

Red Rock Resorts (NASDAQ:RRR) had its target price trimmed by Citigroup from $69.00 to $65.00. Citigroup currently has a buy rating on the stock.

Sunrun (NASDAQ:RUN) had its target price lowered by Citigroup from $14.00 to $13.00. Citigroup currently has a buy rating on the stock.

Sunrun (NASDAQ:RUN) had its price target cut by JPMorgan Chase & Co. from $12.00 to $11.00. They currently have an overweight rating on the stock.

SolarEdge Technologies (NASDAQ:SEDG) had its target price trimmed by JPMorgan Chase & Co. from $38.00 to $31.00. JPMorgan Chase & Co. currently has a neutral rating on the stock.

SolarEdge Technologies (NASDAQ:SEDG) had its target price trimmed by Citigroup from $30.00 to $24.00. The firm currently has a sell rating on the stock.

Steven Madden (NASDAQ:SHOO) had its target price trimmed by Needham & Company LLC from $52.00 to $45.00. They currently have a buy rating on the stock.

Scotts Miracle-Gro (NYSE:SMG) had its price target reduced by JPMorgan Chase & Co. from $70.00 to $67.00. JPMorgan Chase & Co. currently has a neutral rating on the stock.

Snap (NYSE:SNAP) had its price target cut by JPMorgan Chase & Co. from $6.00 to $5.00. JPMorgan Chase & Co. currently has an underweight rating on the stock.

Stanley Black & Decker (NYSE:SWK) had its price target increased by Citigroup from $107.00 to $140.00. Citigroup currently has a buy rating on the stock.

Sysco (NYSE:SYY) had its target price cut by Citigroup from $87.00 to $84.00. Citigroup currently has a neutral rating on the stock.

Timken (NYSE:TKR) had its price target lowered by Citigroup from $140.00 to $125.00. The firm currently has a buy rating on the stock.

Trex (NYSE:TREX) had its target price boosted by Citigroup from $52.00 to $59.00. They currently have a neutral rating on the stock.

US Foods (NYSE:USFD) had its target price raised by TD Cowen from $119.00 to $125.00. They currently have a buy rating on the stock.

VICI Properties (NYSE:VICI) had its price target lowered by Citigroup from $36.00 to $30.00. The firm currently has a buy rating on the stock.

CLEAR Secure (NYSE:YOU) had its price target increased by JPMorgan Chase & Co. from $55.00 to $75.00. They currently have an overweight rating on the stock.

Zimmer Biomet (NYSE:ZBH) had its price target increased by Citigroup from $99.00 to $117.00. They currently have a neutral rating on the stock.